Because PPARγ activation may have a dual effect on prostate cancer (21), results derived from cellular studies should be carefully interpreted and clinical trials in humans are pivotal to elucidate the roles of different TZD compounds in the development or prevention of prostate cancer. The gene discussed is PPARG; the disease is prostate carcinoma.